These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12415797)

  • 1. [Familiarity and heredity of tumors in function of an early surgical therapeutic approach].
    Ricevuto E; Di Rocco ZC; Cianci G; Bisegna R; Casilli F; De Galitiis F; Cannita K; Calista F; Porzio G; Bafile A; Vicentini R; Resta V; De Rubeis G; Martinotti S; Ficorella C; Marchetti P
    Suppl Tumori; 2002; 1(3):S89-91. PubMed ID: 12415797
    [No Abstract]   [Full Text] [Related]  

  • 2. Preventive surgery is associated with reduced cancer risk and mortality in women with BRCA1 and BRCA2 mutations.
    Domchek SM; Rebbeck TR
    LDI Issue Brief; 2010; 16(2):1-4. PubMed ID: 21545057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic surgery recommended for BRCA1 carriers.
    Cancer Discov; 2014 May; 4(5):OF1. PubMed ID: 24795013
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetics: predisposition and management.
    Legare RD
    Clin Obstet Gynecol; 2011 Mar; 54(1):180-90. PubMed ID: 21278518
    [No Abstract]   [Full Text] [Related]  

  • 5. Preventing breast, ovarian cancer in BRCA carriers: rational of prophylactic surgery and promises of surveillance.
    Agnantis NJ; Paraskevaidis E; Roukos D
    Ann Surg Oncol; 2004 Dec; 11(12):1030-4. PubMed ID: 15545500
    [No Abstract]   [Full Text] [Related]  

  • 6. BRCA1 and BRCA2 variants of uncertain significance. Part two: medical management.
    Miller-Samuel S; Rosenberg A; Berger A; Gomella L; Loren D; Morris GJ
    Semin Oncol; 2011 Oct; 38(5):605-11. PubMed ID: 21943665
    [No Abstract]   [Full Text] [Related]  

  • 7. Pretest genetic counseling informs patients with BRCA mutation.
    Printz C
    Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
    [No Abstract]   [Full Text] [Related]  

  • 8. Risk management options elected by women after testing positive for a BRCA mutation.
    Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
    Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from genetic testing.
    Esserman L; Kaklamani V
    JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
    [No Abstract]   [Full Text] [Related]  

  • 10. Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate.
    Kauff N; Robson M
    Nat Rev Clin Oncol; 2015 Sep; 12(9):505-6. PubMed ID: 26196251
    [No Abstract]   [Full Text] [Related]  

  • 11. Familial breast and ovarian cancers.
    Arai M; Utsunomiya J; Miki Y
    Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choices--and uncertainties--for women with BRCA mutations.
    Couzin J
    Science; 2003 Oct; 302(5645):592. PubMed ID: 14576419
    [No Abstract]   [Full Text] [Related]  

  • 14. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
    Roukos DH; Briasoulis E
    Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Inherited breast and ovarian cancers].
    Gerdes AM; Ejlertsen B
    Ugeskr Laeger; 2006 Jun; 168(24):2367-9. PubMed ID: 16822422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers.
    Biglia N; Mariani L; Ponzone R; Sismondi P
    Maturitas; 2008 Jun; 60(2):71-7. PubMed ID: 18472232
    [No Abstract]   [Full Text] [Related]  

  • 17. [Clinical counseling and care of women with genetic predisposition to breast and ovarian carcinoma].
    Schmutzler RK; Kempe A; Kiechle M; Beckmann MW
    Dtsch Med Wochenschr; 1999 May; 124(18):563-6. PubMed ID: 10356583
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA testing: ethics lessons for the new genetics.
    Sherwin S
    Clin Invest Med; 2004 Feb; 27(1):19-22. PubMed ID: 15061582
    [No Abstract]   [Full Text] [Related]  

  • 20. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.
    Leegte B; van der Hout AH; Deffenbaugh AM; Bakker MK; Mulder IM; ten Berge A; Leenders EP; Wesseling J; de Hullu J; Hoogerbrugge N; Ligtenberg MJ; Ardern-Jones A; Bancroft E; Salmon A; Barwell J; Eeles R; Oosterwijk JC
    J Med Genet; 2005 Mar; 42(3):e20. PubMed ID: 15744030
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.